Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial

Published:2023-06 Issue:10394 Volume:401 Page:2138-2147
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Schneider Martina,Narciso-Abraham Marivic,Hadl Sandra,McMahon Robert,Toepfer Sebastian,Fuchs Ulrike,Hochreiter Romana,Bitzer Annegret,Kosulin Karin,Larcher-Senn Julian,Mader Robert,Dubischar Katrin,Zoihsl Oliver,Jaramillo Juan-Carlos,Eder-Lingelbach Susanne,Buerger Vera,Wressnigg Nina

Publisher

Elsevier BV

Subject

General Medicine

Reference25 articles.

1. Arthritogenic alphaviruses—an overview;Suhrbier;Nat Rev Rheumatol,2012

2. Chikungunya: a paradigm of emergence and globalization of vector-borne diseases;Simon;Med Clin North Am,2008

3. Chikungunya: epidemiology, pathogenesis, clinical features, management, and prevention;Vairo;Infect Dis Clin North Am,2019

4. Chikungunya infection in travelers;Hochedez;Emerg Infect Dis,2006

5. The global emergence of chikungunya infection: an integrated view;Manzoor;Rev Med Virol,2022

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Less common viral infections;Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant;2025

2. New Highly Selective Antivirals for Chikungunya Virus identified from the Screening of a Drug-Like Compound Library;Current Microbiology;2024-09-04

3. Pathogenicity and virulence of chikungunya virus;Virulence;2024-09

4. First immunogenicity and safety data on live chikungunya vaccine in an endemic area;The Lancet Infectious Diseases;2024-09

5. Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents;The Lancet Infectious Diseases;2024-09